Zilbrysq Autoinjector Wins FDA Approval for Generalized Myasthenia Gravis, but Patients Must Wait Until Early 2027
FDA approved a once-daily Zilbrysq autoinjector for generalized myasthenia gravis. It launches in early 2027 with the same meningococcal infection warning.
Medical Daily ·